{"analyses":[{"ciLowerLimit":"0.289","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.627","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.425","statisticalMethod":"Log-rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.52","upperLimit":"10.97","value":"7.5"},{"groupId":"OG001","lowerLimit":"3.61","upperLimit":"4.80","value":"3.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"To determine the efficacy by assessment of TDT compared to placebo. compared to placebo. The TDT was defined as time to study treatment discontinuation or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Randomised participants received orally 300 mg bd which were made up of 2 x 150 mg tablets bd with 100 mg tablets used to manage dose reductions.","id":"OG000","title":"Olaparib 300 mg Twice Daily (bd)"},{"description":"Randomised participants received placebo tablets orally 300 mg bd which were made up of 2 x 150 mg tablets bd with 100 mg tablets used to manage dose reductions.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Intention to treat (ITT): All randomised patients, Myriad confirmed Breast cancer susceptibility gene mutation (gBRCAm) subgroup.","reportingStatus":"POSTED","timeFrame":"Up to 4 years","title":"Time From Randomisation to Study Treatment Discontinuation or Death (TDT)","type":"SECONDARY","unitOfMeasure":"Months"}